Filter by
-
UMB Dataset
Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
- Authors
- Peter DoshiBansri DesaiKyungwan HongJohn H. Powers, III
- Description
Clinicians prescribing therapeutic agents newly approved by the FDA must rely on the information reported through drug labels (also known as “package inserts”). Ideally, labels should incorporate details regarding key efficacy information, including the magnitude of treatment benefit, and measures of precision and random error (confidence intervals and p values). This study assessed the degree to which...
- Subject
-
Drug Labeling/standards
- Access Rights
- Unrestricted access
-
UMB Dataset
The Possible Harms of Statins: What do Product Labels, Patient Package Inserts, and Pharmacy Leaflets Tell Us?
- Authors
- Peter DoshiJan SielukAnna Hung
- Description
This cross-sectional study evaluated three sources of written medical documents for consistency of language with regard to the adverse effects of 8 single-agent statins. Full prescribing information (PI’s, also called package inserts or drug labels), patient package inserts (PPIs), and pharmacy leaflets differ according to regulatory status, issuing body, and intended audience. The first two sources...
- Subject
-
Consumer Health Information/standardsDrug Labeling/standards
- Timeframe
- 2015
- Access Rights
- Unrestricted access